Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Filing marks first protein-based vaccine submitted to MHRA for authorization
Through the mission an entire ecosystem for services from treatment to critical research will be created in every corner of the country
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Ivenix selected Tritan MXF for the pump exterior because of its excellent chemical resistance and durability in the face of the aggressive disinfection protocols needed to prevent the spread of healthcare-associated infections
Second interchangeable biosimilar product approved by agency
Subscribe To Our Newsletter & Stay Updated
